Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
$0.22
$0.22
$0.17
$0.40
$6.47M0.521,730 shsN/A
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
$5.51
$4.00
$6.92
$200.47M2.16189,500 shs64,100 shs
NVLNF
Novelion Therapeutics
$0.70
-1.2%
$0.70
$0.51
$1.00
$13.77M2.15261,364 shs26,900 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$0.16
$0.15
$0.12
$1.52
$2.50M1.281.62 million shs112,297 shs
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
0.00%0.00%-6.36%-12.96%-40.61%
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
0.00%0.00%0.00%0.00%0.00%
NVLNF
Novelion Therapeutics
0.00%0.00%0.00%0.00%0.00%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
+0.63%-4.82%+14.29%-4.88%-84.16%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
NVLNF
Novelion Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.5817 of 5 stars
3.53.00.00.00.60.01.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
N/AN/AN/AN/A
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
N/AN/AN/AN/A
NVLNF
Novelion Therapeutics
N/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
3.00
Buy$3.251,926.18% Upside

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
$50.67M0.13$0.04 per share5.75$0.63 per share0.34
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
$10.72M0.00N/A23.28$3.63 per share0.00
NVLNF
Novelion Therapeutics
$130.43M0.11N/AN/A($4.69) per share-0.15
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$13.27M0.19N/AN/A$1.72 per share0.09

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
-$30K-$0.01N/AN/A-0.76%-2.05%-1.47%5/6/2024 (Estimated)
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
-$8.56MN/A0.00N/AN/A-328.56%-16.12%-14.17%N/A
NVLNF
Novelion Therapeutics
-$108.33MN/A0.00N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$5.15M-$0.97N/AN/AN/A-41.24%-58.93%-26.92%6/19/2024 (Estimated)

Latest SNOA, NVLNF, INBP, and KMPH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/12/2024Q2 2024
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
N/A-$0.01-$0.01-$0.01N/A$11.51 million
2/8/202412/31/2023
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.21-$0.06+$0.15-$0.04N/A$3.14 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
N/AN/AN/AN/AN/A
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
N/AN/AN/AN/AN/A
NVLNF
Novelion Therapeutics
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
N/A
2.93
0.84
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
0.14
10.10
10.10
NVLNF
Novelion Therapeutics
N/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
4.07
3.11

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
25.25%
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
19.39%
NVLNF
Novelion Therapeutics
48.64%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
14130.10 million16.37 millionNot Optionable
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
2234.51 million34.13 millionOptionable
NVLNF
Novelion Therapeutics
10919.62 millionN/ANot Optionable
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
915.61 million14.17 millionNot Optionable

SNOA, NVLNF, INBP, and KMPH Headlines

SourceHeadline
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United StatesSonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States
finanznachrichten.de - April 9 at 10:39 AM
Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United StatesSonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States
accesswire.com - April 9 at 7:30 AM
Sonoma Pharmaceuticals Reports Recent Publication…Sonoma Pharmaceuticals Reports Recent Publication…
pharmiweb.com - April 4 at 10:28 AM
Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract InfectionsSonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections
accesswire.com - April 4 at 7:30 AM
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor ConferencesSonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences
finanznachrichten.de - March 28 at 9:52 PM
Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor ConferencesSonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences
accesswire.com - March 28 at 4:01 PM
Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other TopicalsSonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals
accesswire.com - March 27 at 7:30 AM
Sonoma Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagSonoma Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
finance.yahoo.com - February 10 at 2:56 PM
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial ResultsSonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial Results
finance.yahoo.com - February 8 at 4:32 PM
Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-the-Counter Skincare Product for Daily UseSonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-the-Counter Skincare Product for Daily Use
finance.yahoo.com - January 23 at 9:51 AM
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial ResultsSonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial Results
finanznachrichten.de - November 13 at 5:52 PM
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial ResultsSonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial Results
finance.yahoo.com - November 13 at 5:52 PM
Sonoma Pharmaceuticals Inc SNOASonoma Pharmaceuticals Inc SNOA
morningstar.com - November 11 at 10:31 PM
Sonoma Pharmaceuticals Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation at the Symposium on Advanced Wound Care Fall ConferenceSonoma Pharmaceuticals Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation at the Symposium on Advanced Wound Care Fall Conference
finance.yahoo.com - November 3 at 8:49 AM
US Stocks Mixed; Bristol Myers Posts Upbeat EarningsUS Stocks Mixed; Bristol Myers Posts Upbeat Earnings
benzinga.com - October 26 at 6:54 PM
Crude Oil Down 2.5%; Mastercard Posts Upbeat EarningsCrude Oil Down 2.5%; Mastercard Posts Upbeat Earnings
markets.businessinsider.com - October 26 at 6:54 PM
Dow Dips Over 100 Points; US GDP Growth Tops ExpectationsDow Dips Over 100 Points; US GDP Growth Tops Expectations
benzinga.com - October 26 at 1:54 PM
Sonoma Pharmaceuticals, Inc. Announces Pricing of $1.7 Million Public Offering of Common StockSonoma Pharmaceuticals, Inc. Announces Pricing of $1.7 Million Public Offering of Common Stock
finance.yahoo.com - October 26 at 1:54 PM
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.62%U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.62%
msn.com - October 24 at 10:20 PM
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.62%U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.62%
msn.com - October 24 at 5:19 PM
macOS Sonoma now available: Heres whats newmacOS Sonoma now available: Here's what's new
pocketnow.com - September 29 at 3:54 PM
macOS SonomamacOS Sonoma
macrumors.com - September 28 at 12:39 PM
Apple macOS Sonoma system requirements – can macOS 14 run on your Mac?Apple macOS Sonoma system requirements – can macOS 14 run on your Mac?
stuff.tv - September 14 at 7:13 AM
National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn AdvancedNational Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced
finance.yahoo.com - August 15 at 10:23 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Integrated BioPharma logo

Integrated BioPharma

OTCMKTS:INBP
Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.
Zevra Therapeutics logo

Zevra Therapeutics

NASDAQ:KMPH
KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Novelion Therapeutics

OTCMKTS:NVLNF
Novelion Therapeutics Inc., a biopharmaceutical company, develops therapies for individuals living with rare diseases in the United States, Japan, Brazil, and internationally. Its commercial products include metreleptin, a recombinant analog of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPTA brand name; and lomitapide capsule for the treatment of adult patients with homozygous familial hypercholesterolemia under the JUXTAPID and LOJUXTA brands. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.
Sonoma Pharmaceuticals logo

Sonoma Pharmaceuticals

NASDAQ:SNOA
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.